UDG HEALTHCARE PUBLIC LIMITED COMPANY (LON:UDG)

Founded in 1948, UDG Healthcare Plc was established by a group of pharmacists in Ireland as United Drug Chemical Company. In 2013, the group rebranded itself as UDG Healthcare Plc. Since 2000, the group strategically acquired other businesses to build, expand and grow its business across geographies. At present, UDG Healthcare is a leading healthcare company that is engaged in advisory, communication, commercial, clinical, and packaging services to the healthcare industries with operations in more than 29 countries. In 2012, UDG Healthcare got listed on the London stock Exchange and became the constituent of the FTSE 250 index.

The group’ core objective to expand its position in the major markets through organic growth and strategic acquisitions, increasing productivity and efficiency for the satisfaction of its customers and shareholders, by providing high quality, innovative and efficient healthcare solutions to its partners, clients, patients and other stakeholders. It also aspires to deploy capital efficiently and strategically for long-term benefits and high returns with low risk. 

UDG Healthcare operates through its two core divisions: Ashfield and Sharp. Ashfield segment is engaged in advisory, marketing, communication, strategic engagement, and patient solutions. Further, it operates in three divisions: Ashfield Advisory, Ashfield Engage and Ashfield Health.  Ashfield operates in 28 countries and engages around 7,000 employees and serving more than 50 countries across Europe, Asia, North America and South America.  It contributes 64% of total operating profit to the group. The Sharp segment provide Packaging, clinical, manufacturing and technology services to the pharmaceutical industry, it operates in Belgium, Netherlands, Ireland, the US and the UK and contribute 36% of group’s operating profit. The group’s 68% of revenue comes from the North America region, 17% from the UK, and 15% by rest of the world.